Aventis Insulin Analog Lantus® Launched in the USA
A diabetes medication that in less than a year has become one of the leading components of diabetes treatment in Germany, was introduced today in the United States. Lantus® (insulin glargine), the first and only insulin analog that provides 24-hour glucose lowering activity while being administered just once per day, is now available by prescription in US pharmacies.
Lantus is unique in that it has no pronounced peak, and is indicated for once-daily administration at bedtime in the treatment of adult and pediatric patients (6 years of age and older) with type 1 diabetes, or adult patients with type 2 diabetes who require long-acting insulin for the control of hyperglycemia. Lantus was first launched in Germany in June 2000, and has already captured 28 percent of the basal insulin market there.
“This product could change, for the better, the way diabetes is treated,â€
Other news from the department
Most read news
More news from our other portals
Last viewed contents
ChemConnect Names Two New Vice Presidents
Flexible electronics off the roll – more than just luminous film - Fraunhofer FEP works on cost-effective system solutions for flexible devices
Genencor and Goodyear to co-develop renewable alternative to petroleum-derived isoprene - Collaborative research marks a leap forward for the biochemicals market segment and the biobased economy
BASF strengthens market position in chelating agents - Double-digit million investment at Ludwigshafen site
LUM GmbH moves into new headquarters in Berlin-Adlershof
Basell expands its agreement with Hyundai Engineering Plastics to a global scale
Biotage AB Increases Focus on Environmental Market Segments
Oxea yet again expands production capacities for carboxylic acids
Headwaters completes third commercial demonstration of its heavy oil catalyst technology
